Reimbursed Care Access in Tunisia

Currently classified as a strictly controlled substance under Tunisia’s narcotics law (Loi n°92‑52 du 18 mai 1992), with no authorized medical use outside of approved clinical research. Possession, cultivation, manufacture, sale and distribution are prohibited except where specific legislative/regulatory texts permit use in the exclusive domains of medicine, veterinary medicine, pharmacy or authorised scientific research — and no national medical program or reimbursement pathway for psilocybin therapy is available publicly. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of authorised MDMA‑assisted therapy programs or reimbursement pathways in Tunisia; MDMA possession, manufacture and trafficking are criminal offences under the Tunisian narcotics framework. #

There is no public evidence of a Tunisian national marketing authorisation or established reimbursement pathway for esketamine (Spravato) as of February 20, 2026; whereas ketamine (racemate) is used within Tunisian hospitals for anaesthesia and analgesia, esketamine is a proprietary nasal formulation that typically requires specific regulatory approval and a controlled distribution program (REMS or similar) in jurisdictions where it is licensed. International manufacturer communications list approvals in multiple countries but do not provide Tunisia as a jurisdiction of marketing authorisation in public materials; absence of an entry in national registries and lack of published Tunisian clinical/practice guidance for esketamine indicate it is not an on‑label, reimbursed treatment in Tunisia. For context on esketamine’s regulatory model internationally: see the product press materials (manufacturer). # #

Ketamine (ketamine hydrochloride) is an accepted and documented medicine in Tunisian clinical practice for anaesthesia, procedural sedation and acute analgesia in hospitals and emergency departments; Tunisian medical literature reports randomized clinical trials and routine clinical use comparing ketamine to other anaesthetic/analgesic agents, indicating availability in hospital formularies and use by anaesthesiology and emergency medicine services. These peer‑reviewed Tunisian studies demonstrate ketamine’s role in perioperative care and emergency analgesia, which implies regulated medical importation/supply and in‑hospital dispensing for authorised indications (anaesthesia/analgesia). # #

- Regulatory / reimbursement nuance: Ketamine’s established role in anaesthesia and acute care is a standard hospital‑level medicine; however, there is no published national programme or public‑insurance reimbursement pathway for repeated, outpatient ketamine infusions for mood disorders (e.g., treatment‑resistant depression) in Tunisia. Where clinicians use ketamine off‑label for psychiatric indications, those uses would be managed within private practice arrangements or hospital services without a clear, published public reimbursement policy. The national narcotics law allows medical and scientific exceptions under regulatory texts, but such psychiatric off‑label programmes have not been documented as publicly reimbursed in Tunisia. #

Currently classified as a strictly controlled substance under Tunisia’s narcotics law, with no authorised medical use outside approved scientific research. DMT (including in plant‑derived preparations such as ayahuasca) is effectively prohibited for possession, distribution, and cultivation absent explicit research authorisation; there is no public healthcare reimbursement mechanism for DMT therapies. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research; possession, distribution or use outside authorised scientific contexts is prohibited. #

Currently classified as a strictly controlled substance under Tunisia’s narcotics law with no authorised medical use in standard practice; international reporting on ibogaine suggests many countries treat it as either controlled or legally ambiguous, but in Tunisia there is no public evidence of authorised clinics, medical programmes or reimbursement for ibogaine treatment — therefore effectively prohibited outside approved research. # #

Ayahuasca contains DMT and therefore falls under the same strict national controls; possession, importation and use of ayahuasca are not authorized in routine medical practice and are prohibited absent a specific, authorised research or religious exemption — and no such legal religious exemptions or medical programmes are documented in Tunisia. # #

Mescaline is a controlled psychotropic alkaloid under Tunisia’s drug law framework and is not authorised for routine medical use or reimbursement; as with other classic psychedelics, mescaline possession, manufacture and distribution are criminalised except for narrowly authorised scientific or medical research. # #

Phenethylamine derivatives in the 2C family (2C‑X) are controlled under broad psychotropic substance and narcotics provisions of Tunisian law; there is no authorised medical use, no reimbursement pathway, and these substances are treated as illicit with criminal penalties for possession, distribution or manufacture except under authorised scientific research protocols. #